Literature DB >> 25535895

A breast cancer cell microarray (CMA) as a rapid method to characterize candidate biomarkers.

Xinyan Wu1, Muhammad S Zahari, Santosh Renuse, Harrys K C Jacob, Sruthi Sakamuri, Mukul Singal, Edward Gabrielson, Saraswati Sukumar, Akhilesh Pandey.   

Abstract

Tissue microarrays (TMAs) have become an invaluable tool in cancer research to evaluate expression and subcellular localization of proteins in cells and tissues. As the catalogs of candidate biomarkers and therapeutic targets become more extensive, there is a need to characterize and validate these targets and biomarkers in cell lines as a primary biological system in research laboratories. Thus, cell microarrays (CMAs) are useful as a high-throughput screening tool. Here, we constructed a CMA containing 32 publicly available immortalized breast cell lines with the goal of creating a method to rapidly screen for antigens of interest in breast cancer research in a relatively easy, rapid and cost-effective manner. As proof of concept, we performed immunocytochemical staining of the HER2 receptor, as the status of this protein is relevant to breast cancer and has previously been reported for these cell lines. We observed a complete concordance of our staining with the published status of HER2 in these cell lines. In addition, we examined the expression of CD44, epithelial markers EpCAM and E-cadherin and tyrosine phosphoproteins. The labeling of these proteins correlates with the known biology of the cell lines. Our results demonstrate the utility of our method to screen for potential biomarkers and therapeutic targets in breast cancer and we suggest that CMAs be used as a general approach in breast cancer research.

Entities:  

Keywords:  CD44; CMA, cell microarray; E-cadherin; ER, estrogen receptor; EpCAM; HER2; ICC, immunocytochemical staining; IHC, immunohistochemical staining; PR, progesterone receptor; TMA, tissue microarray; TNBC, triple negative breast cancer; biomarker; breast cancer; cell microarray; immunocytochemical staining; phosphorylation

Mesh:

Substances:

Year:  2014        PMID: 25535895      PMCID: PMC4622654          DOI: 10.4161/15384047.2014.961886

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  30 in total

Review 1.  Oncogenic kinase signalling.

Authors:  P Blume-Jensen; T Hunter
Journal:  Nature       Date:  2001-05-17       Impact factor: 49.962

Review 2.  Understanding the dual nature of CD44 in breast cancer progression.

Authors:  Jeanne M V Louderbough; Joyce A Schroeder
Journal:  Mol Cancer Res       Date:  2011-10-04       Impact factor: 5.852

Review 3.  Tyrosine kinases as targets for cancer therapy.

Authors:  Daniela S Krause; Richard A Van Etten
Journal:  N Engl J Med       Date:  2005-07-14       Impact factor: 91.245

4.  Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1998-05-16       Impact factor: 79.321

Review 5.  Morphogenetic roles of classic cadherins.

Authors:  M Takeichi
Journal:  Curr Opin Cell Biol       Date:  1995-10       Impact factor: 8.382

6.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

Authors:  D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich
Journal:  Science       Date:  1989-05-12       Impact factor: 47.728

7.  High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer.

Authors:  Gilbert Spizzo; Philip Went; Stephan Dirnhofer; Peter Obrist; Ronald Simon; Hanspeter Spichtin; Robert Maurer; Urs Metzger; Brida von Castelberg; Rahel Bart; Shanna Stopatschinskaya; Ossi Robert Köchli; Philip Haas; Friedrich Mross; Markus Zuber; Holger Dietrich; Susanne Bischoff; Martina Mirlacher; Guido Sauter; Guenther Gastl
Journal:  Breast Cancer Res Treat       Date:  2004-08       Impact factor: 4.872

8.  Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.

Authors:  Jesper V Olsen; Blagoy Blagoev; Florian Gnad; Boris Macek; Chanchal Kumar; Peter Mortensen; Matthias Mann
Journal:  Cell       Date:  2006-11-03       Impact factor: 41.582

9.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

10.  The CD44+/CD24- phenotype is enriched in basal-like breast tumors.

Authors:  Gabriella Honeth; Pär-Ola Bendahl; Markus Ringnér; Lao H Saal; Sofia K Gruvberger-Saal; Kristina Lövgren; Dorthe Grabau; Mårten Fernö; Ake Borg; Cecilia Hegardt
Journal:  Breast Cancer Res       Date:  2008-06-17       Impact factor: 6.466

View more
  5 in total

1.  Loss of ARID1A expression is associated with systemic inflammation markers and has important prognostic significance in gastric cancer.

Authors:  Xuan Wang; Keying Che; Tao Shi; Qin Liu; Xinyun Xu; Hongyan Wu; Lixia Yu; Baorui Liu; Jia Wei
Journal:  J Cancer Res Clin Oncol       Date:  2022-03-16       Impact factor: 4.553

Review 2.  Living Cell Microarrays: An Overview of Concepts.

Authors:  Rebecca Jonczyk; Tracy Kurth; Antonina Lavrentieva; Johanna-Gabriela Walter; Thomas Scheper; Frank Stahl
Journal:  Microarrays (Basel)       Date:  2016-05-26

Review 3.  Progress in the clinical detection of heterogeneity in breast cancer.

Authors:  Jun-Long Song; Chuang Chen; Jing-Ping Yuan; Sheng-Rong Sun
Journal:  Cancer Med       Date:  2016-10-24       Impact factor: 4.452

4.  Redox-Sensitive and Hyaluronic Acid-Functionalized Nanoparticles for Improving Breast Cancer Treatment by Cytoplasmic 17α-Methyltestosterone Delivery.

Authors:  Somayeh Rezaei; Soheila Kashanian; Yadollah Bahrami; Luis J Cruz; Marjan Motiei
Journal:  Molecules       Date:  2020-03-05       Impact factor: 4.411

5.  Cancer cell line microarray as a novel screening method for identification of radioresistance biomarkers in head and neck squamous cell carcinoma.

Authors:  Johannes Routila; Karri Suvila; Reidar Grénman; Ilmo Leivo; Jukka Westermarck; Sami Ventelä
Journal:  BMC Cancer       Date:  2021-07-29       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.